HEALTH PROFESSIONAL · SOURCE READING
Treatment of Recurrent and Progressive Pancreatic Neuroendocrine Tumors
Source: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
There is no established therapy for pancreatic neuroendocrine tumors that recur or progress after previous therapy.[1] Deciding on further treatment depends on many factors, including:
Source links and citations
The specific cancer.
Previous treatment.
Site of recurrence.
Individual patient considerations.
Attempts at re-resection of local tumors that have recurred or re-resection of metastatic lesions may offer palliation, when technically feasible. Intra-arterial chemotherapy is a consideration for patients with liver metastases. Patients with hepatic-dominant disease and substantial symptoms caused by tumor bulk or hormone-release syndromes may benefit from continuous-infusion intra-arterial chemotherapy or procedures that reduce hepatic arterial blood flow to metastases (hepatic arterial occlusion with embolization or with chemoembolization).[2-7] Such treatment may also be combined with systemic chemotherapy. A variety of systemic agents have shown biological or palliative activity,[1,8] including:
Somatostatin analogues.
Tyrosine kinase inhibitors (e.g., sunitinib).
Temozolomide.
Vascular endothelial growth factor pathway inhibitors.
Mammalian target of rapamycin inhibitors (e.g., everolimus).
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice
Triangle